Quick Answer
Beam Therapeutics Inc. reported Stockholders Equity of $1.24 billion for the year ending 2025.
- Beam Therapeutics Inc. showed an increase of +68.8% in Stockholders Equity from 2024 to 2025.
- This data is from Beam Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: -$132.99 million | Q2 2019: -$151.87 million | Q3 2019: -$172.07 million | Q1 2020: $261.39 million | Q2 2020: $230.82 million | Q3 2020: $200.07 million | Q1 2021: $422.43 million | Q2 2021: $548.55 million | Q3 2021: $853.81 million | Q1 2022: $829.07 million | Q2 2022: $800.16 million | Q3 2022: $714.48 million | Q1 2023: $761.51 million | Q2 2023: $811.64 million | Q3 2023: $778.94 million | Q1 2024: $913.49 million | Q2 2024: $854.09 million | Q3 2024: $791.32 million | Q1 2025: $1.12 billion | Q2 2025: $1.05 billion | Q3 2025: $966.00 million.
- Over the full 8 years of available data (2018 to 2025), Beam Therapeutics Inc.'s Stockholders Equity has grown by 1,154.8%.
- Historical annual values: Fiscal year 2025: $1.24 billion | Fiscal year 2024: $733.55 million | Fiscal year 2023: $981.33 million | Fiscal year 2022: $733.47 million | Fiscal year 2021: $826.74 million | Fiscal year 2020: $245.56 million | Fiscal year 2019: -$201.10 million | Fiscal year 2018: -$117.41 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: